To report the long-term results of prostate brachytherapy followed by external beam radiotherapy (EBRT) in men with a positive seminal vesicle biopsy (+SVB).
Introduction
Definitive therapy for prostate cancer is very successful when the tumour is limited to the gland. Extension into the seminal vesicles (SVs), stageT3b, is associated with an increased risk of both local and systemic relapse. Radical prostatectomy (RP) data show that between 6% and 26% of patients who present with clinical stage T1-T2 will have pathological T3b disease after RP [1] [2] [3] . The likelihood of encountering extension outside of the gland is significantly related to the presenting PSA level, Gleason score, and clinical stage, at the time of diagnosis [4] . Whilst surgeons have developed an effective strategy to manage men who are found with pT3b after RP, the radiation oncologist often treats higher risk/stage patients the same, regardless of the possibility that SV involvement (SVI) may be present.
Whilst tables or nomograms can have a predictive value, they cannot definitively exclude the presence of SV disease. Direct puncture by transrectal biopsy is more likely to accurately exclude the presence of prostate cancer extension [4] [5] [6] . Patients with positive biopsy have an increased risk of pelvic lymph node metastases, which can be determined in patients electing radiotherapy (RT) before treatment by laparoscopic pelvic lymph node dissection (LPLND) [4] . The presence of pT3b disease without evidence of pelvic metastases represents a treatment challenge, as standard external beam RT (EBRT) has high failure rates in men with locally advanced disease [7] . Pretreatment determination of SVI by biopsy followed by LPLND could identify those patients with pT3bN0M0 disease. The delivery of higher RT doses by combining seed implantation with EBRT targeting the SVs, as well as the prostate, has the potential to treat an extended field required in these patients [8] . In the present study, we report our long-term experience in men with pT3b disease diagnosed by SV biopsy (SVB) and treated with permanent brachytherapy to the prostate and proximal SVs followed by EBRT.
Patients and Methods
Between 1990 and 2011, 1981 men who presented with T1-3 prostate cancer were treated with permanent prostate brachytherapy alone or combined with androgen-deprivation therapy (ADT) and/or EBRT and followed for a mean (range) of 9 (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) years. When the prostate brachytherapy programme was initiated in 1990, all newly diagnosed patients were offered SVB under TRUS guidance (three from each side) and LPLND at the time of implantation [4] . By 1996, the indications for SVB were limited to men presenting with a PSA level of > 10 ng/mL, stage ≥T2b or Gleason score ≥7 [9] . Likewise, the indications for LPLND were restricted to men with a positive SVB (+SVB) [4] . These procedures and their results have been previously reported [4] .
Men identified as pT3bN0M0 and who had negative bone, CT scan, and LPLND, were offered a protocol that included 3 months of ADT, 103 Pd implantation to the prostate and SVs (planning dose 100 Gy) followed 2 months later with 45 Gy of EBRT (1.8 Gy fractions) targeting the prostate and SVs. The ADT was continued for 6 more months (total 9 months) and was either given as monotherapy or in combination with an antiandrogen. A full description of the SV implantation technique has been previously reported [8] . Within 2 months after treatment, CT-based dosimetry was performed with RT doses converted to biological effective doses (BEDs) [10] (Fig. 1a and b ).
Biochemical freedom from failure (BFFF) was computed by the Phoenix definition, freedom from metastasis (FFM) in men with biochemical failure by the absence of a positive bone or CT scan, and cause-specific survival (CSS) by freedom from death in men with clinical recurrence [11] . Association of risk features, which included PSA level, Gleason score and clinical stage to +SVB were compared by chi-squared and linear regression. Means were compared by ANOVA (with bootstrapping) and two-tailed Student's t-test. Survival was computed by Kaplan-Meier estimates with comparisons by log-rank and Cox hazard rates (HRs). Analysis was performed using the Statistical Package for the Social Sciences (SPSSâ) version 20 (SPSS Inc., IBM Corp., Armonk, NY, USA). The data collection and reporting were approved by the Institutional Review Board (GCO#97-427).
Results
The mean (median, range) age and PSA level for the 1981 men were 65.6 (66, 39-85) years and 9.4 (6.7, 0.3-300) ng/ mL, respectively. Of the 1981 men, 615 had a SVB (31%) and of these 53 (9.4%) had +SVBs. All 53 men with a +SVB, who received implantation, also had negative LPLNDs. Stage >T2a, Gleason score >6 and a PSA level of >20 ng/mL were associated with a +SVB (P < 0.001) ( Table 1) . Most of the men with biopsy-positive T3b disease were National Comprehensive Cancer Network (NCCN) Group 3 (48/53, 90.6%). Linear regression was significant for stage (P < 0.001), Gleason score (P < 0.001), and PSA level (P = 0.004). The mean follow-up for men with a negative SVB (-SVB) was 11.2 years (95% CI 10.9-11.5) and for a +SVB was 9.1 years (95% CI 8.3-9.9, P < 0.001).
The BFFF at 10 and 15 years was 81.6% and 76.3% for those with a -SVB compared to 60.6% and 60.6% for those with pT3b (P = 0.001). The mean time free of PSA failure for the -SVB and +SVB groups was 17.7 years (95% CI 16. 3), P < 0.001]. Significant Cox proportion HRs were: HR 1.9 for Gleason score (P < 0.001), HR 1.42 for stage (P = 0.010), HR 0.991 for BED (P = 0.013), and HR 4.48 for +SVB (P = 0.001) ( Table 3) .
Treatment toxicity was determined by changes between initial IPSS, urinary bother, and the need for TURP. The mean (SD) initial IPSS was 3.4 (2.7) for -SVB men vs 4.1 (2.7) in those with a +SVB (P = 0.071). The mean (SD) last IPSS was 3.3 (2.5) vs 3.0 (2.4) (P = 0.428), respectively. The mean (SD) change for both was À0.05 (3.5) vs À1.1 (3.5) (P = 0.051). and 86 men were evaluable, whilst at 15 years, 18 and three were evaluable with -SVBs and +SVBs, respectively. The mean (SD) initial urinary bother score for -SVB was 1.6 (1.4) vs 1.7 (1.3) for +SVB (P = 0.524). The mean (SD) last quality-of-life score was 2.0 (1.5) vs 2.3 (1.6) (P = 0.111), respectively. The mean (SD) change for both was 0.4 (1.7) vs 0.6 (1.8) (P = 0.393).
Discussion
The presence of extraprostatic disease is associated with increased biochemical failure and decreased prostate cancer survival. Whilst surgical patients can be offered adjuvant EBRT when pT3b disease is encountered, those receiving primary RT often have no assessment of this risk and no treatment targeting SVI. There are three methods to assess SVI risk: the use of nomograms, MRI, and direct puncture with histological analysis. Statistical prediction tools have been widely developed for prostate cancer [12] . Lughezzani et al. [13] evaluated three predictive models for SVI: the 2007 update of the Partin tables, the European Society for Urological Oncology (ESUO) criteria, and the nomogram developed by Gallina. The area under the curve for all three was 0.792, 0.692, and 0.805, respectively. The addition of prostate biopsy information has been shown to improve the accuracy of clinical information. Koh et al. [14] , in an analysis of 763 patients with clinical stages T1c-T3 prostate cancer, who were diagnosed by systematic biopsy and treated with RP, constructed clinical nomograms with and without biopsy information. On multivariate analysis, serum PSA level (P < 0.001), primary Gleason grade (P = 0.028), and the percentage of cancer at the base of the prostate (P = 0.005), were the only significant predictors of SVI. Lee et al. [15] performed a similar study in 990 patients with intermediateand high-risk prostate cancer who underwent RP, who were stratified into two groups according to the proportion of positive cores from the prostate base vs positive cores throughout the prostate. The ratio of the base positive-cores was a significant predictor of SVI in multivariate analysis (P < 0.001).
Ko et al. [16] evaluated the ability of MRI to determine SVI in 121 patients who had MRI before robot-assisted RP. The accuracy of MRI imaging was 84.3% for SVI, with false negatives occurring in 52.6%. MRI staging has advanced prostate cancer diagnosis with the addition of targeted fusion biopsy. In a study of 822 men who underwent multiparametric MRI evaluation, fusion-guided biopsy detected SVI in 20/31 (65%) of cases [17] .
Experience with SVB has been reported by several investigators. Allepuz Losa et al. [3] investigated 75 patients who underwent SVBs (two from each side) and found the effectiveness of retrieving SV tissue was 90.9%. Infiltration rates were 69% for disease stage ≥T2b and 68% for a PSA level of >10 ng/mL. We initially reported our results in 222 men with prostate cancer who underwent a staging SVB prior to brachytherapy. In these men, who had six biopsies (three from each SV), we determined concordance for PSA level, Gleason score and stage in 187 men who had RP [9] . In the present study, we again demonstrated the predictive value of PSA level, stage and Gleason score in selecting patients for SVB. In addition, a +SVB has the greatest predictive value for those with the risk of pelvic lymph node metastases, with up to 48% having a positive LPLND [4] .
Determination of pT3b disease after RP and the poorer outcomes associated with invasion of the SVs is well documented. Ward et al. [18] analysed 842 men with cT3 disease who had RP and were followed for 10.3 years.
Freedom from biochemical recurrence for cT3 disease at 10 and 15 years was 43% and 38%, and CSS 90% and 79%, respectively. The HR for systemic relapse was 1.49 in the subgroup with pT3b. Baccala et al. [19] reviewed 6740 patients who had RP of whom 566 (8.4%) had positive SVs.
The 5-and 10-year biochemical relapse-free survival rate was 38.0% and 25.6%, respectively, for patients with positive SVs.
In an analysis of 220 men with SVI, Eggener et al. [20] found the 4-and 7-year biochemical progression-free survival rates were 32% and 22% in the pre-PSA era compared to 50% and 45%, respectively, in the PSA era.
The potential to improve these results has been addressed by the addition of adjuvant RT. Thompson et al. [21] randomised 431 men with pT3N0M0 prostate cancer to 60-64 Gy post-RP RT or observation. Metastasis-free and prostate cancer survival were significantly greater with RT with HRs of 0.71 (95% CI 0.54-0.94; P = 0.016) and 0.72 (95% CI 0.55-0.96; P = 0.023), respectively.
Patients receiving RT rather than surgery do not typically have biopsy assessment of their SVs or treatment targeted to them when positive. Strategies to treat high-risk patients with RT include long-term hormonal therapy, dose escalation, and brachytherapy boost. A number of randomised trials have confirmed that RT dose escalation in patients with high-risk disease conveyed significant benefit in biochemical recurrence-free survival, but it has not been established if the addition of ADT also confers any benefit [22] [23] [24] . However, dose escalation by brachytherapy boost provides a substantially higher BED than EBRT alone [10] . Yang et al. [25] [27] analysed 2234 men with localised prostate cancer treated between 1991 and 2007 with low-dose-rate (LDR) brachytherapy monotherapy (n = 457) or brachytherapy with supplemental EBRT (n = 229), ADT (n = 424), or both (n = 1124). All men had at least one high-risk factor. The use of both brachytherapy plus supplemental EBRT and ADT was associated with a decreased risk of prostate cancer mortality (adjusted HR 0.5, 95% CI 0.2-0.9; P = 0.03) compared with brachytherapy alone.
In a prospective randomised trial of 400 patients with intermediate-and high-risk disease given ADT for 8 months and then treated with 46 Gy EBRT to the whole pelvis; patients were then randomised to receive 32 Gy/16 fractions conformal EBRT boost or LDR-brachytherapy boost prescribed to a minimum peripheral dose of 115 Gy [28] . The 9-year biochemical failure-free survival was 83% with the use of a LDR boost compared to 63% with EBRT boost (HR 0.35, 95% 0.19-0.65; P < 0.001). Whilst these data substantiate the benefits of the higher RT dose with the brachytherapy boost, extraprostatic disease in the SVs is not typically addressed. Thus, patients undergoing combined therapy run the risk of insufficient treatment when the SVs are involved, as these structures only receive the reduced EBRT dose (45-46 Gy). We instituted a combined RT programme in 1993 and added SV implantation to those with +SVBs in June of 1994 [29] . With a mean (range) follow-up of 9 (5-16) years, we report favourable BFFF, FMF and CSS at 15 years of 60.6%, 78.2%, and 70.4%, respectively, in men with +SVBs. The BED for men with SVI was higher than those without involvement, which is consistent with the placement of extra sources in the SVs augmenting the total prostate dose. The technique to implant the SVs, as well as the ability to achieve a meaningful RT dose to the SVs, has been previously described [8, 29] .
The favourable results in the present study should be considered in light of the long-term experience of the practitioners. We started our implant programme in 1990 and developed our own technique for seed implantation. Those with less experience may be reluctant to implant patients with SVI. In addition, whilst these data were prospectively collected, it is a single institution's experience and not a randomised investigation. Lastly, morbidity may be increased by the extra radiation delivered to the SVs, which could potentially increase radiation injury to the bladder neck, ureters, and rectum. We did not observe an increase in urinary morbidity by determining changes in IPSS and urinary bother between the -SVB men and those with an SV implant. In addition, the number of post-implant TURPs was not increased, a finding that might be expected if bladder neck strictures had occurred. Because the SV implant is limited to the proximal SVs, no ureteric strictures were noted.
Whilst the present investigation did not record rectal morbidity, in a previous publication, we did not find increased radiation damage when higher doses were delivered [30] .
Conclusions
Patients with high PSA level, Gleason score and clinical stage have a risk of SVI of 20.3-48.3%, which could be diagnosed by biopsy before considering RT. Men who present with NCCN Group 3 disease have a substantially higher risk than Groups 1 or 2 (14.3% vs 1.8%, P < 0.001). The combination of EBRT and brachytherapy boost might benefit from the additional implantation of the SVs yielding more favourable biochemical control and prostate cancer survival.
